Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 20, 2023Kidney International ReportsOpen Access

The beneficial effects of ertugliflozin on kidney outcomes did not differ when stratified by baseline heart failure status (P=0.22).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does ertugliflozin improve kidney outcomes in patients with heart failure at baseline?

Population

Patients from the VERTIS CV trial, stratified by baseline heart failure

Design

RCT

Follow-up

5 years

Key result

The beneficial effects of ertugliflozin on kidney outcomes did not differ when stratified by baseline heart failure status (P=0.22).

Authors

DCDavid Z.I. CherneyFCFrancesco CosentinoDMDarren K. McGuire

Discussion

Loading...

Member takes

Overview

Ertugliflozin kidney benefits are consistent regardless of baseline heart failure; confirms uniform SGLT2i effects across HF strata in CKD.

Study Design

Type

RCT

Randomization

Randomized

Structured PICO

Does ertugliflozin improve kidney outcomes in patients with heart failure at baseline?

P
Population
Patients with a history of heart failure or left ventricular ejection fraction ≤45% in the VERTIS CV trial.
I
Intervention
Ertugliflozin
O
Outcome
Estimated glomerular filtration rate (eGFR) over time, total 5-year eGFR slopes, and time to first event of a prespecified exploratory kidney composite outcome of sustained ≥40% decrease from baseline eGFR, chronic kidney replacement therapy, or kidney deathcomposite

Main Result

p-value: p=0.22

Ertugliflozin provides consistent kidney benefits in patients regardless of baseline heart failure status.

Cite This Study

Cherney et al. (2023) conducted an RCT in Heart Failure. Ertugliflozin was evaluated on Estimated glomerular filtration rate (eGFR) over time, total 5-year eGFR slopes and time to first event of a prespecified exploratory kidney composite outcome (p=0.22). The beneficial effects of ertugliflozin on kidney outcomes did not differ when stratified by baseline heart failure status (P=0.22).

synapsesocial.com/papers/6aadfbe3537e7deed64f66d0https://doi.org/10.1016/j.ekir.2023.01.011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial2026
  2. 2Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus2022 · 45 citations
  3. 3Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial2025 · 1 citations
  4. 4Safety and efficacy of ertugliflozin on heart failure outcomes across cardiovascular diseases: a systematic review and meta-analysis2026
  5. 5Long‐term weight loss and cardiorenal outcomes by baseline <scp>BMI</scp> in the <scp>VERTIS CV</scp> trial2024 · 3 citations